This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder | MicrobiomeTrials
← Back to trials NCT03065335
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2017-05-25Est. Completion: 2027-01-01
Enrollment target: 150 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Sickle Cell Disease
Background:
Sickle Cell Disease (SCD) is a blood disorder that occurs mainly in people of African descent. Researchers …
Bethesda, United States Completed Dec 9, 2019
Sickle Cell Trait Sickle Cell Disease Sickle Cell Anemia
This study will collect representative blood samples from healthy children and adults and from children and adults who h…
Bethesda, United States
Mood Disorders Anxiety Disorders
This study is intended to help develop new MRI imaging techniques for studying mood and anxiety disorders. Researchers b…
Bethesda, United States